- Home
- BEAT vs IMMX Comparison
BEAT vs IMMX Comparison
Compare BEAT & IMMX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BEAT
- IMMX
- Stock Information
- Founded
- BEAT 2015
- IMMX 2014
- Country
- BEAT United States
- IMMX United States
- Employees
- BEAT N/A
- IMMX N/A
- Industry
- BEAT Retail: Computer Software & Peripheral Equipment
- IMMX Medicinal Chemicals and Botanical Products
- Sector
- BEAT Technology
- IMMX Health Care
- Exchange
- BEAT Nasdaq
- IMMX Nasdaq
- Market Cap
- BEAT 58.0M
- IMMX 65.5M
- IPO Year
- BEAT 2021
- IMMX 2021
- Fundamental
- Price
- BEAT $1.79
- IMMX $2.76
- Analyst Decision
- BEAT Buy
- IMMX Strong Buy
- Analyst Count
- BEAT 1
- IMMX 1
- Target Price
- BEAT $8.00
- IMMX $8.00
- AVG Volume (30 Days)
- BEAT 99.2K
- IMMX 352.4K
- Earning Date
- BEAT 11-06-2025
- IMMX 11-11-2025
- Dividend Yield
- BEAT N/A
- IMMX N/A
- EPS Growth
- BEAT N/A
- IMMX N/A
- EPS
- BEAT N/A
- IMMX N/A
- Revenue
- BEAT N/A
- IMMX N/A
- Revenue This Year
- BEAT N/A
- IMMX N/A
- Revenue Next Year
- BEAT $19.35
- IMMX N/A
- P/E Ratio
- BEAT N/A
- IMMX N/A
- Revenue Growth
- BEAT N/A
- IMMX N/A
- 52 Week Low
- BEAT $0.91
- IMMX $1.34
- 52 Week High
- BEAT $3.48
- IMMX $3.20
- Technical
- Relative Strength Index (RSI)
- BEAT 60.65
- IMMX 72.99
- Support Level
- BEAT $1.74
- IMMX $1.94
- Resistance Level
- BEAT $2.03
- IMMX $2.13
- Average True Range (ATR)
- BEAT 0.11
- IMMX 0.19
- MACD
- BEAT 0.00
- IMMX 0.08
- Stochastic Oscillator
- BEAT 40.00
- IMMX 99.99
About BEAT Heartbeam Inc.
HeartBeam Inc is a medical technology company is focusing on developing and commercializing higher resolution ambulatory Electrocardiogram ("ECG") solutions that enable the detection and monitoring of cardiac disease outside a healthcare facility setting. The Company's ability to develop higher-resolution ECG solutions is achieved through the development of the Company's proprietary and patented Vector Electrocardiography ("VECG") technology platform. The Company has validated this technology and is seeking U.S. Food and Drug Administration ("FDA") clearance for its initial telehealth products.
About IMMX Immix Biopharma Inc.
Immix Biopharma Inc is engaged in the discovery and development of novel cell therapies for hematologic malignancies (blood cancers) and other indications. It is a clinical-stage biopharmaceutical company developing a novel class of Tissue-Specific Therapeutics TM in oncology and inflammation. Its TME Normalization Technology allows drug candidates to circulate in the bloodstream, exit through tumor blood vessels and simultaneously attack all components of the TME. Its product candidates include CAR-T NXC-201 for autoimmune diseases, and IMX-110 for treatment of soft tissue sarcoma.